Passage Bio, Inc. has taken a significant step forward by obtaining stockholder approval for its new equity incentive plan and employee stock purchase plan during a special meeting held on November 5, 2026. This approval is contingent on the completion of a merger with Remix Therapeutics, which is expected to enhance Passage Bio's market position in the biological products sector.

The 2026 Equity Incentive Plan is designed to replace Passage Bio’s previous equity plans and will become effective upon the merger's initial effective time. This plan aims to incentivize employees and align their interests with those of the company’s stockholders. The plan will reserve a total of 5,772,500 shares for issuance, with potential annual increases based on the company’s performance.

Additionally, the stockholders approved the 2026 Employee Stock Purchase Plan, which allows employees to purchase shares at a discounted rate, further promoting employee engagement and retention. The maximum number of shares authorized for this plan is 440,000, with similar annual increases as outlined in the equity incentive plan.

Passage Bio’s stockholders also voted on several proposals related to the merger agreement with Remix. The first proposal, which involves the issuance of shares to Remix's securityholders, was approved, indicating strong support for the merger. This merger is anticipated to create a more robust entity in the biological products market.

As part of the merger, stockholders approved a reverse stock split, which will adjust the number of shares outstanding to ensure compliance with Nasdaq listing requirements. The split ratio will range from 1-for-2 to 1-for-10, with the final ratio to be determined by the companies involved.

Passage Bio, Inc. is listed on Nasdaq under the ticker PASG and specializes in the development of biological products, excluding diagnostic substances. The company is headquartered in Philadelphia, Pennsylvania, and operates as a smaller reporting company.

The filing, with accession number 0001140361-26-042222, outlines the details of the special meeting and the stockholder votes on the various proposals. As the company moves forward with the merger, it aims to leverage these new plans to attract and retain key talent, thereby enhancing its competitive edge in the industry.

Looking ahead, the completion of the merger and the implementation of the new equity plans will be crucial for Passage Bio as it seeks to solidify its position in the market. The company has not specified further actions or filings following this approval.